WHO ICTRP trial
Effect of oral semaglutide on glucose variability and oxidative stress in type 2…
JPRN-UMIN000046938 · Japan Primary Registries Network (JPRN) · Not Recruiting
Key facts
| Trial ID | JPRN-UMIN000046938 |
|---|---|
| Public title | Effect of oral semaglutide on glucose variability and oxidative stress in type 2 diabetes patients |
| Scientific title | Effect of oral semaglutide on glucose variability and oxidative stress in type 2 diabetes patients - Effect of oral semaglutide on glucose variability and oxidative stress in type 2 diabetes patients |
| Primary sponsor | Showa University School of Medicine, Division of Diabetes and Endocrinology, Department of Internal Medicine |
| Registry | Japan Primary Registries Network (JPRN) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | Not selected |
| Countries | Japan |
| Conditions | Type 2 diabetes mellitus |
| Interventions | semaglutide 7mg (maintenance dose reached after 4 weeks of 3 mg semaglutide once daily). Continue DPP-4 inhibitors (regular dose) |
| Registration date | Feb 17, 2022 |
| Target size | 58 |
| Registry page | center6.umin.ac.jp |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: